Total submissions: 15
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000255624 | SCV000322047 | pathogenic | not provided | 2021-12-06 | criteria provided, single submitter | clinical testing | Published functional studies demonstrate that R722W disrupts RARB2 mRNA synthesis by deregulating several transcriptional steps and destabilizes the architecture of the evolutionarily conserved general transcription factor IIH (TFIIH) (Singh et al., 2015); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 18817897, 25431422, 7920640, 15494306, 26577220, 23232694, 23221806, 23039039, 20944642, 25620205, 22705887, 12820975, 27862069, 8571952, 28724667, 19085937, 31282071, 31589614, 32732226, 31980526, 31803976) |
Equipe Genetique des Anomalies du Developpement, |
RCV000677676 | SCV000803818 | pathogenic | Cerebrooculofacioskeletal syndrome 2 | 2014-01-09 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000763052 | SCV000893533 | pathogenic | Cerebrooculofacioskeletal syndrome 2; Xeroderma pigmentosum, group D; Trichothiodystrophy 1, photosensitive | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000255624 | SCV001248922 | pathogenic | not provided | 2018-07-01 | criteria provided, single submitter | clinical testing | |
Women's Health and Genetics/Laboratory Corporation of America, |
RCV001199920 | SCV001370695 | pathogenic | Trichothiodystrophy | 2020-05-28 | criteria provided, single submitter | clinical testing | Variant summary: ERCC2 c.2164C>T (p.Arg722Trp) results in a non-conservative amino acid change in the encoded protein sequence. Five of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 2.4e-05 in 251074 control chromosomes. c.2164C>T has been reported in the literature in individuals affected with Trichothiodystrophy (e.g. Takayama_1996, Taylor_1997, Usuda_2011, Zhou_2013). These data indicate that the variant is likely to be associated with disease. At least one publication reports experimental evidence evaluating an impact on protein function and showed that p.Arg722Trp affected normal activity (e.g. Singh_2015). Three clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as pathogenic. Based on the evidence outlined above, the variant was classified as pathogenic. |
Rady Children's Institute for Genomic Medicine, |
RCV001265586 | SCV001443751 | pathogenic | ERCC2-related conditions | 2019-11-20 | criteria provided, single submitter | clinical testing | This variant has been previously reported as a compound heterozygous and homozygous change in patients with trichothiodystrophy (PMID: 8571952, 19085937, 20944642, 23232694, 26577220). Functional studies using patient fibroblast cell lines show that this variant impedes the recruitment of transcription repair factor TFIIH to sites of DNA damage, at least in part by weakening the interaction of ERCC2 with the GTF2H2 subunit (PMID: 18817897, 25620205). Another study using patient fibroblast cells shows that this variant results in a drastic reduction in the expression of collagen type VI alpha1 subunit, an important component of soft connective tissues, due to impaired TFIIH function (PMID: 23221806). This variant is present in the heterozygous state in the gnomAD population database at a frequency of 0.003% (9/276898) and thus is presumed to be rare. The c.2164C>T (p.Arg722Trp) variant affects a highly conserved amino acid and is predicted by multiple in silico tools to have a deleterious effect on protein function. Based on the available evidence, the c.2164C>T (p.Arg722Trp) variant is classified as Pathogenic. |
Laboratory for Molecular Medicine, |
RCV001449816 | SCV001653116 | pathogenic | Hypotrichosis simplex | 2021-03-05 | criteria provided, single submitter | clinical testing | The p.Arg722Trp variant in ERCC2 has been reported in >10 individuals with trichothiodystrophy (TTD) as homozygous or in trans with a second pathogenic ERCC2 variant (Takayama 1996 PMID:8571952, Stefanini 2010 PMID:19931493, Pehlivan 2012 PMID:23039039). It has also been identified in 0.005% (6/128882) of European chromosomes by gnomAD (http://gnomad.broadinstitute.org); however, this frequency is low enough to be consistent with a recessive carrier frequency. This variant has also been reported in ClinVar (Variation ID 16792). In vitro functional studies support an impact on protein function (Pehlivan 2012 PMID:23039039, Singh 2015 PMID:25620205). Mouse models have shown that this variant causes TTD (deBoer 1998 PMID: 9651581). In summary, this variant meets criteria to be classified as pathogenic for autosomal recessive TTD. ACMG/AMP Criteria applied: PS3, PM3_Strong, PM2_Supporting. |
Invitae | RCV000255624 | SCV002216805 | pathogenic | not provided | 2023-10-24 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with tryptophan, which is neutral and slightly polar, at codon 722 of the ERCC2 protein (p.Arg722Trp). This variant is present in population databases (rs121913026, gnomAD 0.004%). This missense change has been observed in individual(s) with photosensitive trichothiodystrophy (PMID: 31282071, 31803976). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 16792). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ERCC2 protein function with a positive predictive value of 80%. For these reasons, this variant has been classified as Pathogenic. |
Preventiongenetics, |
RCV003398537 | SCV004120072 | pathogenic | ERCC2-related condition | 2023-02-09 | criteria provided, single submitter | clinical testing | The ERCC2 c.2164C>T variant is predicted to result in the amino acid substitution p.Arg722Trp. This variant was reported in the homozygous and compound heterozygous states in individuals with trichothiodystrophy (TTD) (Pehlivan et al. 2012. PubMed ID: 23039039; Takayama et al. 1996. PubMed ID: 8571952; Botta et al. 2008. PubMed ID: 19085937; Usuda et al. 2011. PubMed ID: 20944642; Brauns et al. 2016. PubMed ID: 26577220; Miguet et al. 2016. PubMed ID: 27862069; Leemans et al. 2019. PubMed ID: 31803976). Functional studies of cells isolated from patients with this variant showed high sensitivity to UV light and decreased DNA repair (Takayama et al. 1996. PubMed ID: 8571952; Nishiwaki et al. 2008. PubMed ID: 18817897). A homozygous mouse model for the p.Arg772Trp variant showed an earlier on-set of age-related vascular phenotypes (Durik et al. 2012. PubMed ID: 22705887). This variant is reported in 0.0047% of alleles in individuals of European (Non-Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/19-45855493-G-A). This variant is interpreted as pathogenic. |
Baylor Genetics | RCV000677676 | SCV004194669 | pathogenic | Cerebrooculofacioskeletal syndrome 2 | 2023-05-30 | criteria provided, single submitter | clinical testing | |
OMIM | RCV000018283 | SCV000038562 | pathogenic | Trichothiodystrophy 1, photosensitive | 1994-06-01 | no assertion criteria provided | literature only | |
Service de Génétique Moléculaire, |
RCV000677676 | SCV001432347 | pathogenic | Cerebrooculofacioskeletal syndrome 2 | no assertion criteria provided | clinical testing | ||
Genome Diagnostics Laboratory, |
RCV000255624 | SCV001808663 | pathogenic | not provided | no assertion criteria provided | clinical testing | ||
Joint Genome Diagnostic Labs from Nijmegen and Maastricht, |
RCV000255624 | SCV001951010 | pathogenic | not provided | no assertion criteria provided | clinical testing | ||
Clinical Genetics DNA and cytogenetics Diagnostics Lab, |
RCV000255624 | SCV001973214 | pathogenic | not provided | no assertion criteria provided | clinical testing |